Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 733100
Species: Homo sapiens
RGD Object: Gene
Symbol: BCL2
Name: BCL2 apoptosis regulator
Acc ID: CHEBI:47344
Term: alvocidib
Definition: A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.
Chemical ID: MESH:C077990
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
BCL2decreases expressionEXP 6480464CTDalvocidib results in decreased expression of BCL2 mRNA; alvocidib results in decreased expression of BCL2 proteinPMID:10887097 PMID:12589031 PMID:15972445
BCL2decreases response to substanceEXP 6480464CTDBCL2 protein mutant form results in decreased susceptibility to alvocidib; BCL2 protein results in decreased susceptibility to alvocidibPMID:12170773 PMID:12517783
BCL2increases expressionEXP 6480464CTDalvocidib results in increased expression of BCL2PMID:10995888
BCL2multiple interactionsEXP 6480464CTD[alvocidib co-treated with Gemcitabine] results in decreased expression of BCL2 protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein]; BCL2 protein results in decreased susceptibility to [alvocidib co-treated with Epothilones]PMID:12170773 PMID:12517783 PMID:15770523
BCL2decreases expressionISOBcl2 (Mus musculus)6480464CTDalvocidib results in decreased expression of BCL2 proteinPMID:12734434
Go Back to source page   Continue to Ontology report